Jeffrey Sevigny, MD brings more than 15 years of industry neuroscience clinical research experience to Acumen. He is currently chief medical officer of Prevail Therapeutics, Inc., a clinical stage biotechnology company developing a pipeline of gene therapies for Parkinson’s and other neurodegenerative disorders. He was recently Chairman of the Alzheimer’s Association Research Roundtable, whose mission is to advance the research, development, and management of new treatments for Alzheimer’s disease. Dr. Sevigny joined Prevail from F. Hoffmann-La Roche AG, where he was Vice President and Global Head of Translational Medicine Neuroscience. Prior to Roche, he was Senior Director of Clinical Development at Biogen, where he led the development of the company’s early and late stage neurodegeneration portfolio. Before that, he held positions at Novartis AG and Merck & Co. Earlier in his career, Dr. Sevigny held academic appointments as Assistant Professor of Neurology at Albert Einstein School of Medicine and Assistant Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons.
Dr. Sevigny earned his MD from Tufts University School of Medicine and an AB in biochemistry from Bowdoin College. He completed a neurology residency at the Neurological Institute of New York at Columbia University Medical Center and a fellowship in Aging & Dementia and Neuro-Epidemiology at Sergievsky Center at Columbia University and Columbia University Mailman School of Public Health.